. 2022 Mar 17;7(3):188–199. doi: 10.1530/EOR-21-0098
This work is licensed under a Table 3.
Demographics of all bearings (n = 79). Data are presented as mean ± s.d. or as n (%).
| Variable | Primary bearing | ||
|---|---|---|---|
| MoM | CoC | Others | |
| n | 38 | 32 | 9* |
| Primary surgery | |||
| Mean age at primary surgery in years | 56.2 ± 14.9 | 50.5 ± 13.1 | 54.4 ± 19.9 |
| Indications for primary surgery (%) | |||
| Primary osteoarthritis | 16 (42.1%) | 11 (34.4%) | 3 (33.3%) |
| Avascular necrosis | 2 (5.3%) | 4 (12.5%) | 1 (11.1%) |
| Fracture | 3 (7.9%) | 1 (3.1%) | 0 (0%) |
| Dysplasia | 2 (5.3%) | 0 (0%) | 0 (0%) |
| Hip pain | 0 (0%) | 1 (3.1%) | 0 (0%) |
| Unknown | 15 (39%.5) | 15 (46.9%) | 5 (55.6%) |
| Male/female (%) | 20/13 (52.6%/34.2%) | 20/12 (62.5%/37.5%) | 6/2 (66.7%/22.2%) |
| Primary PHACT complaints (%) | 34 (89.5%) | 1 (3.1%) | 3 (33.3%) |
| Revision PHACT complaints (%) | 4 (10.5%) | 31 (96.9%) | 6 (66.7%) |
| Cobalt toxicity level in ppb | 123.7 ± 96.8 | 1.078.2 ± 1.267.5 | 379.4 ± 369.3 |
| Mean age at onset of symptoms in years | 58.3 ± 12.9 | 59.3 ± 10.9 | 58.5 ± 11.5 |
| Mean time in years at onset of symptoms after primary surgery (range) | 2.1 (0–13) | 8.8 (4–15) | 4.1 (2–12) |
| Revision surgery | |||
| Mean age at revision surgery in years | 60.7 ± 11.2 | 56.9 ± 11.4 | 58.5 ± 8.8 |
| Indication for revision surgery (%) | |||
| Systemic symptoms | 29 (76.3%) | 1 (3.1%) | 2 (22.2%) |
| Fracture CoC | 0 (0%) | 29(90.6%) | 2 (22.2%) |
| (Chronic) pain | 3 (7.9%) | 1 (3.1%) | 0 (0%) |
| Recurrent dislocations | 2 (5.3%) | 0 (0%) | 0 (0%) |
| Protrusion acetabulum | 1 (2.6%) | 0 (0%) | 0 (0%) |
| Fracture | 1 (2.6%) | 0 (0%) | 0 (0%) |
| Osteolysis | 1 (2.6%) | 0 (0%) | 0 (0%) |
| Unknown | 1 (2.6%) | 1 (3.1%) | 5 (55.6%) |
| Bearing after revision (%) | |||
| MoM | 0 (0%) | 6 (18.8%) | 0 (0%) |
| CoC | 0 (0%) | 0 (0%) | 0 (0%) |
| MoP | 5 (13.2%) | 21 (65.6%) | 2 (22.2%) |
| CoP | 12 (31.6%) | 0 (0%) | 0 (0%) |
| ToP | 1 (2.6%) | 0 (0%) | 0 (0%) |
| CoM/MoC | 1 (2.6%) | 3 (9.4%) | 0 (0%) |
| Girdlestone | 2 (5.3%) | 0 (0%) | 0 (0%) |
| Not suitable | 16 (42.1%) | 0 (0%) | 0 (0%) |
| Unknown | 1 (2.6) | 2 (6.25) | 6 (66.7%) |
| Mean follow-up time in months | 13 ± 12.2 | 11 ± 13.5 | 15 ± 25.3 |
*MoP: 2; CoP: 2; unknown: 7.
CoC, ceramic-on-ceramic; CoM, ceramic-on-metal; CoP, ceramic-on-polyethylene; MoC, metal-on-ceramic; MoM, metal-on-metal; MoP, metal-on-polyethylene; PHACT, prosthetic hip-associated cobalt toxicity; ppb, parts per billion; ToP, titanium-on-polyethylene.